U.S., Feb. 5 -- ClinicalTrials.gov registry received information related to the study (NCT06806579) titled 'Atezolizumab-bevacizumab and Other Immunotherapies: Real-life Experience for Treatment of Hepatocellular Carcinoma' on Jan. 10.
Brief Summary: - Background Hepatocellular carcinoma (HCC), is the fifth most common cancer worldwide and the third leading cause of cancer-related death. In most cases (about 80%), HCC develops in a cirrhotic liver - a condition where the liver has been damaged over time, leading to scarring. This makes treatment more challenging.
This study will gather and analyze data from patients treated in real-world settings to:
1. Understand the effectiveness and safety of new treatment combinations (e.g., atezoliz...